Original BioMedicals Co., Ltd.

Original BioMedicals Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of innovative pharmaceuticals to address unmet medical needs. Founded in 2011 and headquartered in Taipei, the company focuses on the development of new drugs using existing active ingredients, with particular emphasis on novel dosage forms, administration regimens, and controlled release technologies. Its core product pipeline includes candidates targeting radiation protection, mitigation of chemotherapy-induced toxicity, treatment of type 2 diabetes, cyanide detoxification, and advanced antibiotic formulations. Leveraging expertise in nanocomposite microcell-based drug delivery, Original BioMedicals creates therapies designed to improve patient outcomes, particularly in oncology, endocrinology, and critical care. The company’s operations involve not only drug development but also the provision of research and development services, primarily serving domestic clients in Taiwan. With a lean workforce and a focus on innovation in drug delivery systems, Original BioMedicals plays a distinctive role in Taiwan’s pharmaceutical and biotechnology sector by transforming established chemistries into modern, clinically valuable therapies.